CliffBio
biologic

Kanjinti

trastuzumab-anns

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameKanjinti
Active ingredienttrastuzumab-anns
Strength150MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.